25 June 2015 
EMA/CHMP/357351/2015  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (initial authorisation) 
Pregabalin Accord 
pregabalin 
On 25 June 2015, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion, recommending the granting of a marketing authorisation for the medicinal product Pregabalin 
Accord, intended for the treatment of epilepsy and generalised anxiety disorder. The applicant for this 
medicinal product is Accord Healthcare Limited. 
Pregabalin Accord will be available as 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 
mg hard capsules. The active substance of Pregabalin Accord is pregabalin, a gamma-aminobutyric acid 
(GABA) analogue (ATC code N03AX16). Pregabalin modulates neuronal excitability in the central nervous 
system.  
Pregabalin Accord is a generic of Lyrica, which has been authorised in the EU since 6 June 2004. Studies 
have demonstrated the satisfactory quality of Pregabalin Accord, and its bioequivalence to the reference 
product Lyrica. A question and answer document on generic medicines can be found here. 
The full indication is:  
“Epilepsy 
Pregabalin Accord is indicated as adjunctive therapy in adults with partial seizures with or without 
secondary generalisation. 
Generalised Anxiety Disorder 
Pregabalin Accord is indicated for the treatment of Generalised Anxiety Disorder (GAD) in adults.” 
Detailed recommendations for the use of this product will be described in the summary of product 
characteristics (SmPC), which will be published in the European public assessment report (EPAR) and 
made available in all official European Union languages after the marketing authorisation has been 
granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Telephone  +44 (0)20 3660 6000  Facsimile +44 (0)20 3660 5520 
Send a question via our website www.ema.europa.eu/contact 
An agency of the European Union   
© European Medicines Agency, 2015. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
  
 
 
 
  
                                                
